82 completed, 27 terminated, 20 active not recruiting, 17 unknown. 90 Phase 2, 48 Phase 1, 34 Phase 3, 12 Not applicable, 4 Early Phase 1.
Follow etoposide phosphate: new trials by email Literature Review of etoposide phosphate trials Research Report on etoposide phosphate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors Olaparib, Gemcitabine, Docetaxel - Germ Cell Cancer | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 36 | 2027-03-01 | 2026-10-01 |
| ALL Backbone in AYAs Blinatumomab, Oncaspar, Cyclophosphamide - Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 67 | 2026-04-03 | 2026-08-17 |
| Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation Cytarabine IT, hydrocortisone, Cisplatin - CNS Embryonal Tumor, CNS, Medulloblastoma | Early Phase 1 | Recruiting | C17 Council | 15 | 2025-09-23 | 2026-07-14 |
| Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of California, Davis | 25 | 2025-07-31 | 2026-06-30 |
| Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) Rituximab, Etoposide, Prednisone - Lymphoma, Lymphoma, B-Cell | Phase 2 | Recruiting | Jennifer Amengual | 30 | 2025-04-14 | 2026-05-27 |
| Tazemetostat Plus CHOP in 1L T-cell Lymphoma Tazemetostat, Doxorubicin, Vincristine - Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Withdrawn | Eric Jacobsen, MD | 2024-12-24 | 2026-04-01 | |
| N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma DANYELZA, Sargramostim, Cytoxan - High-risk Neuroblastoma, Neuroblastoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2024-07-22 | 2026-08-28 |
| A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Odronextamab, Loncastuximab tesirine, Rituximab - B-cell Non Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | University of Birmingham | 210 | 2024-05-02 | 2026-02-20 |
| A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma Odronextamab, Ifosfamide, Carboplatin - B-Cell Non-Hodgkin Lymphoma (B-NHL) | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 216 | 2024-02-15 | 2026-05-11 |
| FUS Etoposide for DMG Etoposide; Oral, 50 Mg, Focused ultrasound with neuro-navigator-controlled sonication - Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 1 | Recruiting | Columbia University | 10 | 2023-06-05 | 2026-01-28 |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin - Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1875 | 2023-05-11 | 2026-10-22 |
| Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies Etoposide, Doxorubicin, Cyclophosphamide - B-cell Lymphoma, Burkitt Lymphoma | Phase 1 | Active not recruiting | Medical College of Wisconsin | 11 | 2023-01-26 | 2026-10-14 |
| Nivolumab 40 mg in Combination With Chemo-Immunotherapy for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate - Primary Mediastinal Lymphoma | Phase 3 | Active not recruiting | National Research Center for Hematology, Russia | 60 | 2022-04-01 | 2026-10-08 |
| Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas Rituximab, Etoposide, Copanlisib - Burkitt Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 8 | 2022-03-24 | 2024-07-09 |
| Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) Pembrolizumab, Doxorubicin, Vinblastine - Classical Hodgkin Lymphoma | Phase 2 | Completed | Merck Sharp & Dohme LLC | 146 | 2021-10-07 | 2025-06-06 |
| Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Primary Mediastinal Large B-Cell Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 244 | 2021-10-05 | 2026-10-01 |
| Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation Polatuzumab Vedotin, Rituximab, Etoposide - Richter Syndrome, Chronic Lymphocytic Leukemia | Phase 2 | Active not recruiting | Weill Medical College of Cornell University | 20 | 2021-09-24 | 2026-09-25 |
| Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) Pembrolizumab, MK-4830, Boserolimab - Small Cell Lung Cancer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 122 | 2021-07-15 | 2026-08-13 |
| Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis Ruxolitinib, Dexamethasone, Etoposide - Hemophagocytic Lymphohistiocytosis | Phase 1 / Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 10 | 2021-07-13 | 2026-04-24 |
| A Study of N9 Chemotherapy in Children With Neuroblastoma Cyclophosphamide, Topotecan, Vincristine - Neuroblastoma, Pediatric Cancer | Early Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2021-06-22 | 2026-08-07 |
Showing 20 of 167. Sign in to see all of them.
Lymphoma (29) · Lymphoma, Large B-Cell, Diffuse (18) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (18) · Lymphoma, Non-Hodgkin (17) · Neuroblastoma (16) · Leukemia, Myeloid, Acute (14) · Central Nervous System Neoplasms (13) · Hodgkin Disease (13) · Leukemia (13) · Small Cell Lung Carcinoma (10) · Brain Neoplasms (9) · Sarcoma (9) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Recurrence (8) · Burkitt Lymphoma (7)
Children's Oncology Group (18) · National Cancer Institute (NCI) (12) · St. Jude Children's Research Hospital (8) · Washington University School of Medicine (7) · Merck Sharp & Dohme LLC (5) · OHSU Knight Cancer Institute (5) · Stanford University (5) · University of Nebraska (4) · Alliance for Clinical Trials in Oncology (3) · Barbara Ann Karmanos Cancer Institute (3) · Children's Cancer and Leukaemia Group (3) · City of Hope Medical Center (3) · Dana-Farber Cancer Institute (3) · M.D. Anderson Cancer Center (3) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (3)
United States (130) · Canada (32) · Australia (26) · United Kingdom (17) · Puerto Rico (12) · Switzerland (12) · Germany (11) · France (9) · Italy (9) · Netherlands (8) · Spain (8) · New Zealand (7) · China (6) · Ireland (6) · Austria (5)
Edward A. Neuwelt, MD (3) · Brian Kushner, MD (2) · Edward A Neuwelt (2) · Frank Berthold, MD (2) · Geoffrey Uy, M.D. (2) · Julie M Vose, MD (2) · Margaret Kasner, MD (2) · Sally Arai (2) · Sharon L. Gardner, MD (2) · Steven G DuBois (2) · Wen-Kai Weng (2) · A. McMillan (1) · Alain Mina, M.D. (1)
PMID 37505794, PMID 34028986, PMID 16525139, PMID 19144982, PMID 20164695, PMID 20934233, PMID 21328522, PMID 21480204, PMID 21602899, PMID 21636711, PMID 22228634, PMID 22308295, PMID 22442346, PMID 22493293, PMID 22689675, PMID 23024237, PMID 23091096, PMID 23370364, PMID 23471307, PMID 23664013, PMID 23890779, PMID 24419114, PMID 24969797, PMID 25001888, PMID 25092781, PMID 26018967, PMID 26254812, PMID 26346136, PMID 26920889, PMID 27000274, PMID 27133823, PMID 27458307, PMID 27465021, PMID 27561722, PMID 27581518, PMID 27863192, PMID 28419486, PMID 28751559, PMID 28787430, PMID 28883080, PMID 30049811, PMID 30157803, PMID 30563754, PMID 30957229, PMID 31545689, PMID 32330099, PMID 32464282, PMID 32730187, PMID 33080007, PMID 33586581
U10CA098543 (6), U10CA180886 (6), 2023 (3), U10CA180821 (3), P30CA022453 (2), P30CA033572 (2), P30CA036727 (2), U10CA031946 (2), 2009 (1), 2014 (1), 2017 (1), P01CA081403 (1), P30CA006516 (1), P30CA016058 (1), P30CA093373 (1)